Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07035652Phase 1Not Yet Recruiting

The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations

Role: lead

NCT06272747Phase 1Completed

Study of XH-S003 in Healthy Volunteers

Role: lead

NCT06981091Phase 2Not Yet Recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Role: lead

NCT06978699Phase 2Recruiting

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Role: lead

NCT05946876Phase 1Completed

A Phase 1 Study of XH-S003 in Healthy Volunteers

Role: lead

NCT06236841Phase 1Not Yet Recruiting

A Phase I Study of XH-S004 in Healthy Volunteers

Role: lead

NCT06204419Phase 1Unknown

A Phase I Study of XH-S002 in Healthy Volunteers

Role: lead

All 7 trials loaded